PoreWise One finding · Human trial · 2024
Study title
Successful treatment of solar lentigines by topical application of stabilized cysteamine: A vehicle-controlled, double-blind randomized study
- Kind of evidence
- Human trial 2024 · 30 people · people with solar lentigines · PMID 38410492
- Measured outcome
- Skin effect
- Year
- 2024
- Who was studied
- 30 people with solar lentigines
- Sample size
- 30
- Measured outcome
- In 30 people with solar lentigines, a stabilised cysteamine cream reduced colourimetric values by 40% and VAS scores by 40% over 12 weeks, versus 2% for both with the vehicle cream.
- Certainty
- Moderate
- Who was measured
- People with solar lentigines on the hands, applying the cream once daily for 12 weeks.
- Study limits
- Small sample (30), lesions on the hands.
Where it comes from
- Successful treatment of solar lentigines by topical application of stabilized cysteamine: A vehicle-controlled, double-blind randomized study
Published by Health Science Reports (Saki N, et al.) · Last checked 2026-11-10
Skin concerns studied
Other findings on the same ingredient or concern
- Skin effectA double-blind, placebo-controlled randomized trial of Serratulae quinquefoliae folium, a new source of beta-arbutin, in selected skin hyperpigmentations
In a randomized, placebo-controlled, double-blind trial of 102 women with melasma or solar lentigo, a cream with 2.51% arbutin applied twice daily for 8 weeks lightened discolouration in 75.86% of the melasma group and 56.00% of the solar-lentigo group.
Human trial · 2015 · 102 people · women (54 study / 48 control) with melasma or solar lentigo · Women aged 26-55 with melasma or solar lentigo, applying a 2.51% arbutin cream twice daily for 8 weeks. · The active was an aqueous extract standardised to 2.51% arbutin.
- Skin effectA randomized controlled study to evaluate the depigmenting activity of L-ascorbic acid plus phytic acid-serum vs. placebo on solar lentigines
In a double-blind, vehicle-controlled trial of 30 people with two or more solar lentigines, a serum with 10% L-ascorbic acid and 2% phytic acid lowered the pigmentation index of the treated lesions over three months while the vehicle-treated lesions stayed stable (P <= 0.003 from month 1 to month 4). Six adverse events, mostly halo depigmentation, were judged possibly related to the product.
Human trial · 2011 · 30 people · healthy subjects with two or more solar lentigines · Pigmentation index, dermoscopic pigmentation and brightness (L*) of solar lentigines over three months, with two months of follow-up. · The serum combines two actives. Each person applied the product to one side of the body and the vehicle to the other. 30 people, and six halo-depigmentation events were possibly related to the product. The authors call for larger studies.
- Skin effectEfficacy of D-pigment dermocosmetic lightening product for solar lentigo lesions of the hand: A randomized controlled trial
In 36 people with solar lentigo lesions on the hands, a dermocosmetic lightening product improved papillary brightness, contrast, luminance and redness significantly more than a moisturising control over 12 months.
Human trial · 2019 · 36 people · subjects, 72 solar lentigo lesions on the hands · Adults with solar lentigo lesions on the hands, followed for 12 months. · Lesions were on the hands.
- Skin effectProspective, randomized, double-blind assessment of topical bakuchiol and retinol for facial photoageing
In a 12-week randomized, double-blind trial of 44 people, both 0.5% bakuchiol and 0.5% retinol significantly reduced wrinkle surface area and hyperpigmentation; bakuchiol caused less scaling and stinging.
Human trial · 2019 · 44 people · adults with facial photoageing · Adults with facial photoageing using bakuchiol twice daily or retinol once daily for 12 weeks. · Small sample (44).
- Skin effectEfficacy and Tolerability of Topical 0.1% Stabilized Bioactive Retinol for Photoaging: A Vehicle-Controlled Integrated Analysis
Across six vehicle-controlled studies pooled together (237 on retinol, 234 on vehicle), 0.1% stabilised retinol produced greater improvements from baseline in all signs of photoaging than the vehicle from week 4 through week 12.
Human trial · 2024 · 471 people · participants across six vehicle-controlled studies · Women around 47 years old with mild-to-moderate photoaging, applying the product for 12 weeks. · Pooled analysis of six studies.